← Back to Search

Virus Therapy

Dose level 3 for Age-Related Macular Degeneration

Phase 1 & 2
Waitlist Available
Research Sponsored by Avirmax Biopharma Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
1. Must be willing and able to provide written, signed informed consent.
2. Age: Subjects ≥ 50 and ≤ 89 years of age at the time of signing the informed consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 52 weeks
Awards & highlights

Summary

This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.

Who is the study for?
This trial is for patients with wet age-related macular degeneration (wAMD), including those with symptomatic macular polypoidal choroidal vasculopathy (PCV). Specific eligibility criteria are not provided, but typically include a confirmed diagnosis and no contraindications for treatment.
What is being tested?
The study tests three different doses of ABI-110, an experimental drug delivered through an eye injection, to evaluate its safety and early effectiveness in treating wAMD and PCV.
What are the potential side effects?
While specific side effects are not listed here, intravitreal injections like ABI-110 may cause eye irritation or discomfort, increased intraocular pressure, bleeding inside the eye, or infection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and Tolerability
Secondary study objectives
Immunogenicity
Optimal Dose
Pharmacokinetics
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Group I: Dose level 3Experimental Treatment1 Intervention
High Dose
Group II: Dose level 2Experimental Treatment1 Intervention
Medium Dose
Group III: Dose level 1Experimental Treatment1 Intervention
Low Dose

Find a Location

Who is running the clinical trial?

Avirmax Biopharma IncLead Sponsor
~12 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top